ClinicalTrials.gg
CompletedNCT02301624Updated Feb 5, 2020Results posted

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

A Phase 3 interventional study of Eculizumab and Placebo in Refractory Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 60 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Enrollment
4th of 13
117 · median 20
Started
2014
the only one that year
Phase 3
9 of 19
2 open now
Registered
3rd of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2014, is one of 9 in phase 3, and was the 3rd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).

Read the detailed description

ECU-MG-302 was an extension study designed to provide the participants who completed Study ECU-MG-301 an opportunity to receive eculizumab and collect clinical data to provide long-term safety and efficacy information on eculizumab in participants with refractory gMG.

After receiving blinded study treatment (eculizumab or placebo) in Study ECU-MG-301 for 26 weeks, participants were eligible to enroll in the ECU-MG-302 extension study. Participants were to enter Study ECU-MG-302 within 2 weeks after completing their Week 26 visit in Study ECU-MG-301.

Study ECU-MG-302 consisted of a 4-week Blind Induction Phase to preserve the blinded nature of Study ECU-MG-301, an Open-Label Maintenance Phase (up to 4 years), and a Safety Follow-up visit 8 weeks after the last dose for participants who withdrew from the study or discontinued eculizumab treatment at any time and for any reason after receiving any amount of eculizumab.

03

Conditions studied

  • Refractory Generalized Myasthenia Gravis

Browse trials for

Keywords

  • gMG
  • Myasthenia Gravis
  • safety
  • efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has completed Study ECU-MG-301.
  2. Participant has given written .
  3. Participant was willing and able to comply with the protocol requirements for the duration of the study.
  4. Female participant of must have had a negative pregnancy test (serum human chorionic gonadotropin). All participants were required to practice an effective, reliable, and medically approved regimen during the study and for up to 5 months following discontinuation of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Participants who withdrew from Study ECU-MG-301 as a result of an adverse event related to study drug.
  2. Female participants who were pregnant, breastfeeding, or intended to conceive during the course of the study.
  3. Unresolved meningococcal infection
  4. to murine proteins or to one of the of eculizumab
  5. Any medical condition or circumstances that, in the opinion of the investigator, might have interfered with the participant's participation in the study, posed any added risk for the participant, or confounded the assessment of the participants.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Eculizumab/Eculizumab

    Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams \[mg\]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3. Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study. Eculizumab 1200 mg was administered for up to 4 years in this extension study.

    Biological: Eculizumab · Drug: Placebo

  • Experimental
    Placebo/Eculizumab

    Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3. Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study. Eculizumab 1200 mg was administered for up to 4 years in this extension study.

    Biological: Eculizumab · Drug: Placebo

Interventions

  • BiologicalEculizumab

    Intravenous administration of eculizumab.

  • DrugPlacebo

    Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.

06

What researchers measure

Primary outcomes

  1. Count Of Participants With Treatment-Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) are adverse events with onset on or after the first study drug dose in Study ECU-MG-302. Likewise, treatment-emergent serious adverse events (TESAEs) are serious adverse events that onset on or after the first study drug dose in Study ECU-MG-302. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Day 1 (after dosing) through End of Study (Week 208)

Secondary outcomes

  1. Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score At Week 4 And Week 130

    The MG-ADL scale is a validated 8-item patient-reported outcome measure. Participants assessed their functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb impairment (2 items). These 8 items were not weighted and were individually graded from 0 (normal) to 3 (most severe), providing a total MG-ADL score ranging from 0 to 24 points. A reduction in score indicates improvement in condition. Baseline was defined as the last available assessment prior to treatment (first study drug infusion) with eculizumab in Study ECU-MG-302. Change from Baseline in MG-ADL total score at Week 4 (blind induction phase) and at Week 130 (open-label eculizumab phase) are presented.

    Time frame: Baseline, Week 4 and Week 130

07

Results

Posted Feb 5, 2020

Participant flow

Participants who completed Study ECU-MG-301 (NCT01997229) were eligible to participate in Study ECU-MG-302.

Blind Induction Phase
Participant flow — Blind Induction Phase
MilestoneEculizumab/EculizumabPlacebo/Eculizumab
Started5661
Received at least 1 dose of study drug5661
Completed5561
Not completed10
Withdrew: Withdrawal by subject10
Open-label Maintenance Phase
Participant flow — Open-label Maintenance Phase
MilestoneEculizumab/EculizumabPlacebo/Eculizumab
Started5561
Received at least 1 dose of study drug5561
Completed4344
Not completed1217
Withdrew: Withdrawal by subject48
Withdrew: Adverse event25
Withdrew: Physician decision33
Withdrew: Death21
Withdrew: Participant felt no change in condition10

Outcome measures

PrimaryCount Of Participants With Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) are adverse events with onset on or after the first study drug dose in Study ECU-MG-302. Likewise, treatment-emergent serious adverse events (TESAEs) are serious adverse events that onset on or after the first study drug dose in Study ECU-MG-302. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Day 1 (after dosing) through End of Study (Week 208)
Reported as:
Count of participants · Participants
Count Of Participants With Treatment-Emergent Adverse Events
ParticipantsEculizumab/EculizumabPlacebo/Eculizumab
TEAEs5559
TEAEs leading to withdrawal35
TESAEs3030
TESAEs leading to withdrawal34
Deaths21
SecondaryChange From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score At Week 4 And Week 130

The MG-ADL scale is a validated 8-item patient-reported outcome measure. Participants assessed their functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb impairment (2 items). These 8 items were not weighted and were individually graded from 0 (normal) to 3 (most severe), providing a total MG-ADL score ranging from 0 to 24 points. A reduction in score indicates improvement in condition. Baseline was defined as the last available assessment prior to treatment (first study drug infusion) with eculizumab in Study ECU-MG-302. Change from Baseline in MG-ADL total score at Week 4 (blind induction phase) and at Week 130 (open-label eculizumab phase) are presented.

Time frame:
Baseline, Week 4 and Week 130
Reported as:
Mean · units on a scale
Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score At Week 4 And Week 130
units on a scaleEculizumab/EculizumabPlacebo/Eculizumab
Change from Baseline At Week 4 (Blind Induction)-0.2 ± 1.77-2.4 ± 3.04
Change from Baseline at Week 130 (Open-label)-0.7 ± 4.19-3.9 ± 3.68

Adverse events

Collected over Day 1 after dosing of study drug through Week 208.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab/Eculizumab2/56 (3.6%)30/56 (53.6%)54/56 (96.4%)
Placebo/Eculizumab1/61 (1.6%)30/61 (49.2%)59/61 (96.7%)
Eculizumab (Combined Total)3/117 (2.6%)60/117 (51.3%)113/117 (96.6%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventEculizumab/EculizumabPlacebo/EculizumabEculizumab (Combined Total)
Myasthenia gravisNervous system disorders7/569/6116/117
PyrexiaGeneral disorders3/560/613/117
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/181/201/38
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/563/613/117
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/563/613/117
AnaemiaBlood and lymphatic system disorders2/561/613/117
InfluenzaInfections and infestations2/560/612/117
PneumoniaInfections and infestations2/562/614/117
SepsisInfections and infestations2/561/613/117
Humerus fractureInjury, poisoning and procedural complications2/560/612/117
Most frequent other events
Showing 10 of 79
Most frequent other events
EventEculizumab/EculizumabPlacebo/EculizumabEculizumab (Combined Total)
HeadacheNervous system disorders20/5624/6144/117
NasopharyngitisInfections and infestations20/5622/6142/117
DiarrhoeaGastrointestinal disorders15/5614/6129/117
Upper respiratory tract infectionInfections and infestations12/5615/6127/117
Myasthenia gravisNervous system disorders12/565/6117/117
CoughRespiratory, thoracic and mediastinal disorders12/5610/6122/117
NauseaGastrointestinal disorders9/5613/6122/117
ArthralgiaMusculoskeletal and connective tissue disorders11/5612/6123/117
InfluenzaInfections and infestations11/5610/6121/117
Urinary tract infectionInfections and infestations10/568/6118/117

Baseline characteristics

All eligible enrolled participants who received at least 1 dose of study drug in this extension study.

Age, Continuous
Age, Continuous(years)Eculizumab/EculizumabPlacebo/EculizumabTotal
Mean47.2 ± 15.5247.5 ± 17.8547.4 ± 16.70
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab/EculizumabPlacebo/EculizumabTotal
Female384179
Male182038
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eculizumab/EculizumabPlacebo/EculizumabTotal
Hispanic or Latino81018
Not Hispanic or Latino454893
Unknown or Not Reported336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eculizumab/EculizumabPlacebo/EculizumabTotal
Asian31619
Black or African American022
White474188
Multiple101
Unknown101
Other426
08

Study locations

60 sites
  • Birmingham, Alabama 35233, United States
  • Los Angeles, California 90033, United States
  • Orange, California 92868, United States
  • Palo Alto, California 94304, United States
  • San Francisco, California 94115, United States
  • New Haven, Connecticut 06519, United States
  • Jacksonville, Florida 32209, United States
  • Miami, Florida 33136, United States
  • Tampa, Florida 33612, United States
  • Springfield, Illinois 62702, United States
  • Indianapolis, Indiana 46202, United States
  • Iowa City, Iowa 52242, United States
  • Kansas City, Kansas 66160, United States
  • Baltimore, Maryland 21201-1595, United States
  • Baltimore, Maryland 21287-0876, United States
  • Boston, Massachusetts 02115, United States
  • Burlington, Massachusetts 01805, United States
  • Las Vegas, Nevada 89145, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28207, United States
  • Durham, North Carolina 27710, United States
  • Columbus, Ohio 43210, United States
  • Portland, Oregon 97239, United States
  • San Antonio, Texas 78229, United States
  • Burlington, Vermont 05401, United States
  • Seattle, Washington 98195, United States
  • Buenos Aires, Argentina
  • Edegem, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • São Paulo, Brazil
  • Edmonton, Canada
  • Ostrava - Poruba, Czechia
  • Praha 2, Czechia
  • Arhus C, Denmark
  • Kobenhavn, Denmark
  • Turku, Finland
  • Szeged, Hungary
  • Milano, Italy
  • Napoli, Italy
  • Roma, Italy
  • Chiba, Japan
  • Fukuoka, Japan
  • Hanamaki, Japan
  • Hokkaido, Japan
  • Miyagi, Japan
  • Nagasaki, Japan
  • Osaka-Fu, Japan
  • Osaka, Japan
  • Seoul, Korea, Republic of
  • Amsterdam, Netherlands
  • Barcelona, Spain
  • Madrid, Spain
  • Stockholm, Sweden
  • Ankara, Turkey
  • İzmir, Turkey
  • Kocaeli, Turkey
  • Birmingham, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. PubMed 30767274 ↗
  • Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2255. doi: 10.1007/s11136-019-02204-x. PubMed 31115842 ↗
  • Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2247-2254. doi: 10.1007/s11136-019-02148-2. Epub 2019 Mar 23. Erratum In: Qual Life Res. 2019 Aug;28(8):2255. doi: 10.1007/s11136-019-02204-x. PubMed 30905021 ↗
  • Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K; REGAIN Study Group. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019 Dec 15;407:116419. doi: 10.1016/j.jns.2019.08.004. Epub 2019 Aug 3. PubMed 31698177 ↗
  • Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021 Dec;64(6):662-669. doi: 10.1002/mus.27422. Epub 2021 Oct 14. PubMed 34590717 ↗
  • Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord. 2021 Mar 16;14:17562864211001995. doi: 10.1177/17562864211001995. eCollection 2021. Erratum In: Ther Adv Neurol Disord. 2021 Oct 29;14:17562864211049696. doi: 10.1177/17562864211049696. PubMed 33796147 ↗
  • Nowak RJ, Muppidi S, Beydoun SR, O'Brien FL, Yountz M, Howard JF Jr. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Front Neurol. 2020 Nov 24;11:556104. doi: 10.3389/fneur.2020.556104. eCollection 2020. PubMed 33329303 ↗
  • Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; REGAIN Study Group. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2021 Jan 26;96(4):e610-e618. doi: 10.1212/WNL.0000000000011207. Epub 2020 Nov 23. PubMed 33229455 ↗
  • Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020 Aug;7(8):1327-1339. doi: 10.1002/acn3.51121. Epub 2020 Jul 22. PubMed 32700461 ↗
  • Jacob S, Murai H, Utsugisawa K, Nowak RJ, Wiendl H, Fujita KP, O'Brien F, Howard JF Jr. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Ther Adv Neurol Disord. 2020 May 6;13:1756286420911784. doi: 10.1177/1756286420911784. eCollection 2020. PubMed 32426038 ↗
  • Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18. PubMed 32189108 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jan 2019, 50 months.

Results were first posted in Feb 2020, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 50 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2014
First posted
Nov 26, 2014
StartActual
Nov 12, 2014
Primary completionActual
Jan 15, 2019
CompletionActual
Jan 15, 2019
Results first posted
Feb 5, 2020
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02301624
Responsible party
Sponsor
First posted
Nov 26, 2014
Start date
Nov 12, 2014
Primary completion
Jan 15, 2019
Completion
Jan 15, 2019
Results posted
Feb 5, 2020
Last update
Feb 5, 2020

Study contacts

Marcus Yountz, MD
study director · Alexion Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion